Reason for request
Re-assessment of the actual benefit at the request of the Transparency
Clinical Benefit
| Low |
Le service médical rendu par MEGACE 160 mg est faible dans le traitement palliatif des carcinomes du sein.
|
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
jRYUhd9jsSav53UV
Listen
